Trium Capital LLP bought a new position in shares of HilleVax, Inc. (NASDAQ:HLVX - Free Report) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 378,205 shares of the company's stock, valued at approximately $548,000. Trium Capital LLP owned 0.75% of HilleVax at the end of the most recent quarter.
Other institutional investors and hedge funds have also bought and sold shares of the company. Millennium Management LLC lifted its holdings in HilleVax by 59.6% in the fourth quarter. Millennium Management LLC now owns 411,820 shares of the company's stock worth $852,000 after buying an additional 153,815 shares during the period. Two Sigma Advisers LP lifted its holdings in HilleVax by 76.8% in the fourth quarter. Two Sigma Advisers LP now owns 41,200 shares of the company's stock worth $85,000 after buying an additional 17,900 shares during the period. Takeda Pharmaceutical Co. Ltd. purchased a new stake in HilleVax in the fourth quarter worth about $13,919,000. Bank of Montreal Can lifted its holdings in HilleVax by 47.1% in the fourth quarter. Bank of Montreal Can now owns 35,763 shares of the company's stock worth $74,000 after buying an additional 11,459 shares during the period. Finally, Intech Investment Management LLC purchased a new position in shares of HilleVax during the fourth quarter valued at approximately $26,000. 86.42% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a "neutral" rating and set a $2.00 target price on shares of HilleVax in a report on Monday, March 31st.
Check Out Our Latest Analysis on HLVX
HilleVax Stock Performance
HLVX stock opened at $2.05 on Wednesday. The firm has a market capitalization of $102.79 million, a price-to-earnings ratio of -0.95 and a beta of 0.76. The firm has a 50 day moving average price of $1.93 and a 200-day moving average price of $1.85. HilleVax, Inc. has a 52-week low of $1.34 and a 52-week high of $2.15.
HilleVax (NASDAQ:HLVX - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.25. As a group, sell-side analysts forecast that HilleVax, Inc. will post -2.64 earnings per share for the current fiscal year.
HilleVax Profile
(
Free Report)
HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.
See Also
Want to see what other hedge funds are holding HLVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HilleVax, Inc. (NASDAQ:HLVX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider HilleVax, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HilleVax wasn't on the list.
While HilleVax currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.